| Trial ID: | L2777 |
| Source ID: | NCT00297401
|
| Associated Drug: |
Ruboxistaurin
|
| Title: |
Renal and Peripheral Hemodynamic Function in Patients With Type 1 Diabetes Mellitus
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 1
|
| Interventions: |
DRUG: ruboxistaurin|DRUG: placebo
|
| Outcome Measures: |
Primary: Primary outcomes will be the change in proteinuria, pre- and post-treatment with ruboxistaurin., Baseline and 8 weeks|Change in the renal and peripheral pressor response to hyperglycemia pre and post treatment with ruboxistaurin, Baseline and 8 weeks|Change in the renal and peripheral pressor response to Angiotensin II pre and post-treatment with ruboxistaurin., Baseline and 8 weeks | Secondary: Secondary analyses will consist of the change in endothelial function and vascular compliance pre- and post-treatment with ruboxistaurin., Baseline and 8 weeks
|
| Sponsor/Collaborators: |
Sponsor: Chromaderm, Inc. | Collaborators: Heart and Stroke Foundation of Canada
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
20
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2006-03
|
| Completion Date: |
2007-11
|
| Results First Posted: |
|
| Last Update Posted: |
2016-08-29
|
| Locations: |
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM - 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physcian., Toronto, Ontario, Canada
|
| URL: |
https://clinicaltrials.gov/show/NCT00297401
|
